Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol(DBM)-resistant Yoshida S.C. sarcoma.
作者信息
Csányi E, Halász M
出版信息
Br J Cancer. 1967 Jun;21(2):353-7. doi: 10.1038/bjc.1967.40.
Abstract
摘要
相似文献
1
Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol(DBM)-resistant Yoshida S.C. sarcoma.对1,6 - 二溴 - 双脱氧 - D - 甘露糖醇（DBM）耐药的吉田肉瘤进行的交叉耐药性研究。
Br J Cancer. 1967 Jun;21(2):353-7. doi: 10.1038/bjc.1967.40.
2
Pharmaco-biochemical studies on cytotoxic polyol derivates. I. Effects of 1-6-dibromo-1-6-dideoxy-dulcitol on sensitive, resistant and refractor tumours.细胞毒性多元醇衍生物的药理生化研究。I. 1,6 - 二溴 - 1,6 - 二脱氧卫矛醇对敏感、耐药和难治性肿瘤的作用。
Eur J Cancer (1965). 1969 Sep;5(4):403-14. doi: 10.1016/0014-2964(69)90053-x.
3
The role of the carrying molecule in the cross-resistance against sugar alcohol derivatives.携带分子在对糖醇衍生物的交叉耐药性中的作用。
Eur J Cancer (1965). 1969 Dec;5(6):553-7. doi: 10.1016/0014-2964(69)90003-6.
4
Pharmacology of 1,6-Dibromo-1,6-dideoxy-dulcitol and its Cytostatic effect on transplantable tumours.1,6 - 二溴 - 1,6 - 二脱氧卫矛醇的药理学及其对可移植肿瘤的细胞抑制作用
Arzneimittelforschung. 1967 Aug;17(8):1037-43.
5
Identical karyotypes in acquired drug-resistant sublines of Yoshida sarcoma.吉田肉瘤获得性耐药亚系中的相同核型
Neoplasma. 1974;21(6):665-9.
6
Cytochemical characterization of Yoshida sarcoma cells resistant to dibromodulcitol.对二溴卫矛醇耐药的吉田肉瘤细胞的细胞化学特征
Int J Tissue React. 1984;6(1):43-51.
7
A mitomycin C-resistant Jensen rat sarcoma: chemotherapy studies.
Cancer Res. 1963 Sep;23(8 Pt 2):1475-82.
8
Antitumor effectiveness of improsulfan on nitrogen mustard-resistant Yoshida sarcoma cells.丙磺舒对氮芥耐药吉田肉瘤细胞的抗肿瘤效果。
Chem Pharm Bull (Tokyo). 1977 Nov;25(11):3003-8. doi: 10.1248/cpb.25.3003.
9
Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.环磷酰胺耐药的吉田腹水瘤细胞及其对某些烷化剂的交叉耐药性。
J Cancer Res Clin Oncol. 1979 Jul 27;94(3):257-63. doi: 10.1007/BF00419285.
10
[THE INFLUENCE OF PRELIMINARY TREATMENT OF RATS WITH ALKYLATING SUBSTANCES AND OTHER TOXINS ON THE GROWTH OF YOSHIDA SARCOMA].
Arzneimittelforschung. 1964 Jul;14:746-50.
引用本文的文献
1
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.二溴卫矛醇与放线菌素D、羟基脲及环磷酰胺用于既往未经治疗的恶性黑色素瘤患者的II期评估。
Invest New Drugs. 1987;5(3):293-7. doi: 10.1007/BF00175301.
2
Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.两种烷化剂之间不存在交叉耐药性：卡莫司汀与双功能半乳糖醇。
Cancer Chemother Pharmacol. 1989;24(5):311-3. doi: 10.1007/BF00304764.
3
New drugs under clinical evaluation in the United States.美国正在进行临床评估的新药。
Cancer Chemother Pharmacol. 1978;1(1):15-24. doi: 10.1007/BF00253142.
本文引用的文献
1
[THE EFFECT OF A NEW CYTOSTATIC, 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL, ON HEMATOPOIESIS IN RATS].[一种新型细胞抑制剂1,6-二溴-1,6-二去氧甘露醇对大鼠造血作用的影响]
Arzneimittelforschung. 1965 Mar;15:198-204.
2
3
[EFFECT OF 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL (DBM) ON CHRONIC MYELOID LEUKEMIA].
Orv Hetil. 1964 Mar 22;105:547-9.
4
[Trial treatment of neoplastic diseases by 1,6-dibromomannitol].[用1,6-二溴甘露醇对肿瘤疾病进行试验性治疗]
Rev Fr Etud Clin Biol. 1963 May;8:483-4.
5
Hematological effects of the alkylating agents.烷化剂的血液学效应。
Ann N Y Acad Sci. 1958 Apr 24;68(3):826-33. doi: 10.1111/j.1749-6632.1958.tb42643.x.
Zotero 插件